<DOC>
	<DOCNO>NCT03095638</DOCNO>
	<brief_summary>The aim cross-over study compare relative bioavailability pharmacokinetic parameter 10 mg conventional tablet 5 mg dispersible tablet dolutegravir ( DTG ) 25 mg 50 mg conventional DTG tablet . The study carry 2 part . Part 1 study open-label , 2 period design wash period least 7 day dose period . Subjects randomize receive either single dose five 10 mg DTG tablets one 50 mg DTG tablet crossover manner fast state . Part 2 study 3 period crossover design wash period least 7 day dose period . Subjects randomize receive either single dose five 5 mg DTG tablet ( administer disperse water directly mouth ) one 25 mg DTG tablet crossover manner fast state . Subjects follow-up visit 7-10 day post last dose study treatment . Approximately 14 healthy subject participate Part 1 approximately 24 healthy subject participate Part 2 study . The total duration Part 1 approximately 7 8 week part 2 approximately 8 9 week . TIVICAYÂ® trademark GlaxoSmithKline group company .</brief_summary>
	<brief_title>Bioavailability Study 10 Milligram ( mg ) 5 mg Tablets Versus Conventional Tablets Dolutegravir</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Between 18 65 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac evaluation ( history electrocardiogram [ ECG ] ) . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50 kilogram ( kg ) males &gt; = 45 kg female body mass index ( BMI ) within range 18.5 31.0 kg per meter square ( kg/m^2 ) ( inclusive ) . Male female . Nonreproductive potential define : Premenopausal females one following : Documented tubal ligation ; Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; Hysterectomy ; Documented Bilateral Oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) estradiol level consistent menopause ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Reproductive potential agrees follow one option list Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) 30 day prior first dose study medication 2 week dose study medication completion followup visit . Capable give sign informed consent include compliance requirement restriction . Alanine amino transferase ( ALT ) bilirubin &gt; 1.5x Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . QT correction use Fridericia Formula ( QTcF ) &gt; 450 Milliseconds ( msec ) . Unable refrain use prescription [ ( i.e . nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator ViiV Medical Monitor medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotine containing product within 1 month prior screen . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Creatinine clearance ( CrCL ) &lt; 90 mL/minute . A positive hepatitis B surface antigen ( HBsAg ) positive hepatitis B core antibody negative hepatitis B surface antibody , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 56 day . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dispersible tablet</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Dolutegravir</keyword>
	<keyword>Healthy</keyword>
	<keyword>Conventional tablet</keyword>
</DOC>